European network brings new medical radioisotopes to patients faster
Nuclear therapy and molecular imaging are widely used at hospitals for new promising medical procedures. They can drastically improve the outcome for many medical conditions, and enables treating disseminated cancer in particular. However, its effective development has long been limited by the difficult access to radionuclides not yet commercially available. With PRISMAP, this is about to change. Picture: ©CERN 2018-2021
PRISMAP is the European medical radionuclide programme on the production of high purity radionuclides (radioactive isotopes) by mass separation. It federates a European consortium of the key intense neutron sources, isotope mass separation facilities and high-power accelerators and cyclotrons, with leading biomedical and healthcare research institutes in the active translation of the emerging radionuclides into medical diagnosis and treatment. In PRISMAP, ISOL@MYRRHA receives an important role as future isotopes-production facility and therefore the work-package dedicated emerging infrastructures is led by Lucia Popescu (SCK CEN).
The consortium is coordinated by thierry [dot] stora [at] cern [dot] ch (Dr Thierry Stora) (CERN) and comprises 23 beneficiaries from 13 countries, one European Research Laboratory and an International Organisation. It receives support of leading associations and institutions in the field such as the European Association of Nuclear Medicine (EANM) and the International Atomic Energy Agency (IAEA).
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101008571 (PRISMAP – The European medical radionuclides programme).
Would you like to know more about PRISMAP as a whole?